Business Context and Reporting Period
Axsome Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Form 8-K on November 30, 2017. The filing reports the entry into a material definitive agreement for a registered direct offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $9.5 million from the sale of 1,783,587 units.
- Unit Composition: Each unit consists of one share of common stock and one warrant to purchase one share.
- Offering Price: $5.325 per unit.
- Warrant Terms: Exercisable immediately; expire 53 weeks from the initial exercise date; exercise price of $5.25 per share.
- Placement Agent Fees: H.C. Wainwright & Co., LLC to receive up to 6% of gross proceeds plus up to $35,000 in non-accountable expenses and up to $50,000 for legal and out-of-pocket expenses.
- Agent Warrants: 107,015 warrants issued to the placement agent (6% of shares sold) with an exercise price of $6.6562 per share.
- Net Proceeds: Expected to be approximately $8.8 million after deducting fees and expenses.
Material Changes and Use of Proceeds
The filing does not provide comparative financial data (revenue, profit, or cash flow) as it is a current report regarding a specific financing event rather than a periodic financial statement. The material change is the dilution of existing shareholders through the issuance of new equity and warrants. The Company expects to use the net proceeds to fund the clinical development of its next product candidate, AXS-07, ongoing clinical programs, and for working capital and general corporate purposes.
Outlook, Risks, and Contingencies
The Offering is expected to close on or about December 4, 2017, subject to customary closing conditions. The filing includes standard forward-looking statements cautioning that actual results may differ materially due to risks and uncertainties. Specific risks are referenced in the Company's Form 10-K for the fiscal year ended December 31, 2016. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the closing of the Offering on or about December 4, 2017.
- Confirm the final net proceeds received after all fees and expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant form (Exhibit 4.1) for specific covenants and adjustment mechanisms.
- Monitor the progress of the clinical development of product candidate AXS-07 as the primary use of funds.
- Check subsequent filings for any updates on the exercise of warrants or changes in the Company's capital structure.